Biomerica applies for a PLA code to enhance patient access to its inFoods IBS diagnostic test for personalized IBS management. Biomerica, Inc. has submitted an application to the American Medical ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., a molecular genomics company pioneering precision dermatology, announces the publication of a new clinical study, confirming the clinical utility of ...
Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results ...
IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company ...
Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years. The clinical data for its melanoma detection ...
DermTech's new product could revolutionize how doctors test for skin cancer. 10x Genomics is turbocharging research in cells and genes. Both companies offer disruptive new solutions in their niches of ...
The inFoods ® IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods that may be contributing to IBS symptoms such as bloating, abdominal pain, diarrhea, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback